🔗 Visit the ClinicalTrials.gov page for NCT01813539
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade. | MAbs | 2013 | 0.84 |
| 2 | Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform. | MAbs | 2015 | 0.81 |
| 3 | Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. | J Immunol Res | 2015 | 0.78 |
| 4 | Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. | Ther Adv Med Oncol | 2016 | 0.77 |
| 5 | Future perspectives in cancer immunotherapy. | Ann Transl Med | 2016 | 0.77 |